CRO market to reach $44.4bn by 2021

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/eaglesky)
(Image: Getty/eaglesky)
The global contract research organization (CRO) market is forecasted to grow 12% year-on-year through 2021 – led by IQVIA with 12.4% of the market share.

The prediction is in line with a previous report from Grand View Research​, according to which the market will reach $45.2bn by 2022.

Ravi Kiran, pharmaceutical consultant at The Business Research Company​, told us the 12% growth rate is an acceleration from the 10% growth rate recorded through 2017. Consequently, the market is currently expected to reach $44.4bn by 2021, according to a report published by the research firm.

IQVIA ​is the largest player in the global CRO market​ with a 12.4% share, followed by LabCorp​, ICON​, PAREXEL​, and PPD​.

Read more:​ Sizing up: Does CRO consolidation leave space for smaller firms?

According to the report, North America is the largest region for the production of CRO services, at $18.8bn. CRO consumption in the same market is worth $20.8bn, or about 47% of the global total.

“The large market size can be attributed to the presence of a large number of pharmaceutical companies and extensive drug development activity in the region, especially in the USA,”​ said Kiran.

However, while the use of lower-cost offshore locations for some CRO activities by US pharmaceutical companies results in the differences between production and consumption – the majority of US outsourced activity remains within the country.

Accounting for about 33% of the CRO market, drug discovery was the largest segment by service type in 2017.

fig1

Oncology was the largest the segment by therapeutic area, with about 25% of the total market. However, the smaller metabolic disease segment is growing faster at 17% a year, according to the report.

fig2

“Declining growth in the pharmaceutical market is affecting the CRO industry, though not in the obvious way,”​ Kiran added, noting that the double-digit growth rates of some pharmaceutical and biotechnology companies have recently been shrinking to single digits.

Kiran said: “Pharmaceutical and biotechnology companies have been confronted with the need to minimize their drug production and development costs which have forced most of them to evaluate cost-saving options such as outsourcing.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars